Glioblastoma Drug Pipeline — PatSnap Eureka
Glioblastoma Drug Pipeline: CAR-T, Oncolytic Virus, EGFR ADC & TTFields
Median GBM survival has barely shifted in two decades. Patent and literature signals across CAR-T, oncolytic virotherapy, EGFR-targeted ADCs, and tumor-treating fields reveal where combination strategies are breaking the deadlock.
Why GBM Remains Oncology's Hardest Problem
Glioblastoma multiforme (GBM) is defined by a convergent set of molecular features that have resisted two decades of therapeutic innovation. PatSnap's life sciences intelligence platform identifies EGFR as the most frequently cited primary target across the GBM dataset — appearing in more than a dozen records. EGFR is amplified and/or overexpressed in the majority of GBM tumors, while the truncated variant EGFRvIII — which lacks exons 2–7 and signals constitutively — is highlighted as particularly actionable because of its tumor-restricted expression and absence from normal brain tissue.
As noted by the Hamburg University Hospital review, "despite the long-known enigmatic EGFR gene amplification and protein overexpression in glioblastoma, the potential of EGFR as a target for this tumor type has been unfulfilled," underscoring the translational gap between target biology and clinical outcomes. Downstream of EGFR, the PI3K/AKT/mTOR pathway is identified as the dominant pro-survival cascade, altered in approximately 90% of GBM cases.
Glioma stem cells (GSCs) are explicitly identified as a key mediator of treatment resistance and recurrence, and the blood-brain barrier (BBB) is universally cited as a pharmacokinetic obstacle limiting CNS drug exposure. The immunosuppressive tumor microenvironment (TME), characterized by myeloid cell infiltration and PD-1/PD-L1 axis activation, is consistently flagged as a barrier to both immunotherapeutic and virotherapeutic approaches. Additional targets include podoplanin (PDPN), CD47, CD24, IL-13Rα2, EphA2, EphA3, EphB2, NG2/CSPG4, VEGFR, PDGFR, and NTRK1 fusions.
Four Approaches Reshaping the GBM Treatment Landscape
Retrieved patent and literature signals span cellular immunotherapy, oncolytic virotherapy, targeted conjugates, and electrophysical devices — each addressing distinct vulnerabilities in GBM biology.
CAR-T Cell Therapy
Engineering patient T cells to express chimeric antigen receptors against GBM-associated surface antigens. EGFRvIII-directed CAR-T is the most established approach. A 2022 Nagoya University paper describes Lp2-CAR-T (anti-podoplanin) combined with oncolytic herpes virus G47Δ — one of the few records providing direct evidence for a CAR-T + oncolytic virus combination in GBM. Primary limitations include antigen heterogeneity, T-cell exhaustion, and the immunosuppressive TME. Targets tested include EGFRvIII, IL-13Rα2, EphA2, and GD2.
Phase I/II signalsOncolytic Virotherapy (OVT)
Oncolytic HSV and adenovirus are the dominant platforms. The University of Genova's R-613 is described as "the first oncolytic HSV fully retargeted to EGFRvIII," significantly increasing median survival in orthotopic xenograft models. XVir-N-31 (oncolytic adenovirus) combined with nivolumab produced abscopal effects in a humanized GBM mouse model. Zika virus exploits natural tropism for neural stem/progenitor cells to selectively target GSCs. Computational modeling identifies low stromal density as highly predictive of oHSV therapeutic success.
Phase I/II (oHSV, Delta24-RGD)EGFR ADCs & Targeted Conjugates
Nine ADCs have received regulatory approval across hematological and solid tumor indications, but CNS applications have had "limited success to date" per the Austin Hospital Melbourne review. The EGFR-as-docking-molecule strategy uses EGFR antibodies as carriers for toxins, T cells, oncolytic viruses, and nanoparticles. The QUAD 3.0 ligand-toxin conjugate targeting IL-13Rα2, EphA2, EphA3, and EphB2 simultaneously was "highly cytotoxic to GBM cells, but nontoxic in mice" — a preclinical proof-of-concept for polyvalent receptor-targeted conjugates.
Preclinical → Phase I/IITumor-Treating Fields (TTFields)
Optune triggers antitumor activity by blocking the mitosis of glioma cells under the application of an alternating electric field. A 2018 Sorbonne Universités review states it is "the only recently developed therapy with some efficacy reported on a large number of GBM patients" among reviewed devices and drugs. The mechanism involves disruption of mitotic spindle formation via low-intensity alternating electric fields. Combination of TTFields with immunotherapy has scientific rationale via immunogenic cell death induction but is not yet substantiated by clinical data in this dataset.
Commercially DeployedGBM Target Landscape & Combination Approach Evidence
Key quantitative signals extracted from patent and literature records, visualized to reveal target density, pathway prevalence, and combination rationale.
Key GBM Molecular Target Prevalence
EGFR amplification (~50%), EGFRvIII expression (~25–30%), and PI3K pathway alteration (~90%) define the dominant actionable landscape in GBM based on dataset records.
Combination Approach Evidence Distribution
OVT + checkpoint blockade is the most numerically represented combination in the dataset; CAR-T + OVT holds the strongest mechanistic coherence as a single preclinical proof-of-concept.
Combination Strategies: Where the Evidence Points
The field is converging on multimodal regimens. These are the highest-signal combination approaches in the retrieved dataset.
CAR-T + Oncolytic Virus: The Leading Paradigm
The 2022 Nagoya paper on Lp2-CAR-T + G47Δ represents the clearest preclinical evidence for this combination strategy. The oHSV serves dual roles: direct tumor lysis and immune microenvironment reprogramming to sustain CAR-T activity. This combination addresses the immunosuppressive TME that limits CAR-T persistence in solid tumors — the central mechanistic rationale for pairing these modalities.
OVT + Immune Checkpoint Blockade
The most numerically represented combination in the dataset. XVir-N-31 + nivolumab (anti-PD-1) from University of Tübingen (2022) provides preclinical in vivo evidence for abscopal effects in a humanized GBM model. A triple combination of oHSV + panobinostat (HDAC inhibitor) + PD-1/PD-L1 blockade yields additive antitumor effects in vivo, reflecting the hypothesis that oncolytic immune priming sensitizes GBM to checkpoint blockade.
From Bench to Bedside: Where the Pipeline Stands
Retrieved results contain several clinical translation signals spanning Phase I through commercial deployment. No Phase III positive readouts for CAR-T, EGFR ADC, or oHSV monotherapy in GBM are documented within the retrieved dataset.
| Modality / Agent | Development Stage | Key Signal | Institution / Source |
|---|---|---|---|
| TTFields (Optune) | Commercially Deployed | Only recently developed therapy with "some efficacy reported on a large number of GBM patients" | Sorbonne Universités, 2018 |
| oHSV platforms | Phase I/II | Investigated in clinical trials for GBM for more than a decade; safety confirmed, single-agent efficacy insufficient | MGH / Harvard, 2014; Texas Tech, 2021 |
| Delta24-RGD adenovirus | Phase I/II completed | Phase I/II trial for GBM referenced as "recently completed" | Elisabeth Hospital, Tilburg, 2015 |
| EGFRvIII CAR-T | Phase I | Clinical activity documented in recurrent GBM; durable responses remain limited | CNR Rome, 2021; Henan Provincial, 2021 |
| GDC-0084 (PI3K inhibitor) | Phase I/II | Explicitly identified as "being evaluated in phase I/II clinical trials of GBM treatment" | Xuzhou Medical University, 2023 |
| Nivolumab (CheckMate 143) | Phase III | Did not achieve survival benefits versus bevacizumab in recurrent GBM; neoadjuvant use showed immunological activity | Henan Provincial, 2021 |
| AZD9291 (osimertinib) | Preclinical GBM data | Superior BBB penetration versus earlier-generation TKIs; >10-fold greater potency than erlotinib/gefitinib in GBM cell lines | Xuzhou Medical University, 2022 |
Track Real-Time GBM Clinical Trial Intelligence
PatSnap Eureka monitors patent filings, literature, and trial registrations across all GBM modalities — updated continuously.
What the Pipeline Signals Mean for Drug Developers
EGFR remains the highest-density target in this dataset, but as a single agent it has consistently underperformed clinically. Retrieved results suggest that EGFR targeting strategies are most viable when coupled with downstream pathway blockade (PI3K), alternative delivery mechanisms (ADC payloads, viral retargeting), or cell-based effector platforms (CAR-T). EGFR ADC programs entering the clinic should incorporate combination protocols addressing PI3K bypass resistance from the outset. PatSnap's IP analytics platform can map the competitive patent landscape across EGFR ADC linker-payload systems.
Oncolytic virus efficacy in GBM is predicted computationally to be primarily determined by stromal density, not just viral engineering. Retrieved modeling data suggests patient stratification by tumor stromal composition as a clinical biomarker strategy for OVT trials — a translational opportunity underexplored in current trial designs. The NCI clinical trials database and WHO oncology guidance provide regulatory context for biomarker-stratified trial designs.
The absence of retrieved patent records in this dataset suggests that foundational IP claims for GBM-specific CAR-T constructs, EGFR ADC payloads, and next-generation oHSV platforms may reside in commercial patent portfolios not captured here. Drug developers and IP strategists should conduct targeted freedom-to-operate analyses covering CAR construct architectures (particularly EGFRvIII and podoplanin-targeting designs), oHSV retargeting technologies, and ADC linker-payload systems independently of this literature-focused dataset. PatSnap customers use Eureka to accelerate exactly this type of FTO and landscape analysis.
The combination of TTFields with immunotherapy has scientific rationale via immunogenic cell death induction but is not yet substantiated by clinical data in this dataset — representing a white space for trial design. EPO Espacenet patent searches can identify early-stage IP filings in this white space before they enter clinical development. Access to PatSnap's open API enables programmatic monitoring of emerging TTFields combination filings.
CAR-T + Oncolytic Virus: Mechanistic Rationale
How the two modalities work together to overcome GBM's immunosuppressive tumor microenvironment — the primary barrier to durable CAR-T responses in solid tumors.
CAR-T + oHSV Sequential Mechanism in GBM
oHSV directly lyses tumor cells and reprograms the immunosuppressive TME, creating conditions for sustained CAR-T activity — the mechanistic rationale for the Lp2-CAR-T + G47Δ combination (Nagoya, 2022).
Glioblastoma Drug Pipeline — key questions answered
Median overall survival under standard-of-care surgery, temozolomide chemotherapy, and radiotherapy is 14–20 months — a benchmark that has barely shifted in two decades.
EGFRvIII — which lacks exons 2–7 and signals constitutively — is highlighted as a particularly actionable target because of its tumor-restricted expression and absence from normal brain tissue.
The CAR-T + oncolytic virus combination represents the most scientifically coherent emerging paradigm within this dataset, with oHSV serving dual roles: direct tumor lysis and immune microenvironment reprogramming to sustain CAR-T activity. The Nagoya podoplanin CAR-T + G47Δ study is a proof-of-concept anchor for this strategy.
Tumor-Treating Fields (TTFields/Optune) currently holds the most robust clinical evidence among the non-standard modalities reviewed, with retrieved results noting its anti-mitotic mechanism and efficacy in a large patient cohort.
EGFR TKI monotherapy has consistently failed in clinical trials, with resistance attributed to co-occurring PTEN loss, PI3K pathway bypass, and extracellular domain mutation topology.
The PI3K/AKT/mTOR pathway is identified in multiple results as the dominant pro-survival cascade, altered in approximately 90% of GBM cases.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About GBM →Accelerate Your GBM Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search the full GBM patent and literature landscape — CAR-T, oHSV, EGFR ADC, TTFields, and combination approaches — in one AI-powered platform.
References
- EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise — University Hospital Hamburg Eppendorf, 2017
- A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy — University Medical Center Ulm, 2015
- Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets — New York Medical College, 2015
- Advanced Cell Therapies for Glioblastoma — Metagenomi Inc., 2022
- Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma — First Affiliated Hospital, Zhengzhou University, 2017
- Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma — Nagoya Central Hospital, 2022
- Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments — Case Western Reserve University, 2021
- Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme — Institute of Translational Pharmacology-CNR, Rome, 2021
- Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy — Massachusetts General Hospital / Harvard Medical School, 2014
- The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment — Texas Tech University Health Sciences Center, 2021
- Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma — University of Genova, 2021
- The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model — University of Tübingen, 2022
- Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them? — Austin Hospital, Melbourne, 2021
- Multireceptor targeting of glioblastoma — Wake Forest Baptist Medical Center, 2020
- Glioblastoma Treatments: An Account of Recent Industrial Developments — Sorbonne Universités, 2018
- Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma — Chinese PLA General Hospital, 2021
- PI3K/AKT/mTOR pathway in glioblastoma — NIH/PubMed Central
- NCI Clinical Trials — National Cancer Institute
- EPO Espacenet Patent Search — European Patent Office
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only — it should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.